Radiopharmaceutical tracers for cardiac imaging.

Abstract

Cardiovascular disease (CVD) is the leading cause of death and disease burden worldwide. Nuclear myocardial perfusion imaging with either single-photon emission computed tomography or positron emission tomography has been used extensively to perform diagnosis, monitor therapies, and predict cardiovascular events. Several radiopharmaceutical tracers have recently been developed to evaluate CVD by targeting myocardial perfusion, metabolism, innervation, and inflammation. This article reviews old and newer used in nuclear cardiac imaging.

• Authors: Osamu Manabe, Tatsuya Kikuchi, Arthur J H A Scholte, Mohammed El Mahdiui, Ryuichi Nishii, Ming-Rong Zhang, Eriko Suzuki, Keiichiro Yoshinaga
• Journal: Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology (J Nucl Cardiol) Vol. 25 Issue 4 Pg. 1204-1236 (08 2018) ISSN: 1532-6551 [Electronic] United States
• PMID: 29196910 (Publication Type: Journal Article)

Chemical References

• Radiopharmaceuticals
• Fluorodeoxyglucose F18

Topics

• Apoptosis
• Atherosclerosis (diagnostic imaging)
• Energy Metabolism
• Fluorodeoxyglucose F18
• Humans
• Myocardial Perfusion Imaging (methods)
• Positron Emission Tomography Computed Tomography
• Positron-Emission Tomography
• Radiopharmaceuticals
• Sympathetic Nervous System (diagnostic imaging, physiopathology)
• Tomography, Emission-Computed, Single-Photon (methods)